1. Home
  2. NXP vs ESPR Comparison

NXP vs ESPR Comparison

Compare NXP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Select Tax Free Income Portfolio

NXP

Nuveen Select Tax Free Income Portfolio

HOLD

Current Price

$14.06

Market Cap

744.2M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.14

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXP
ESPR
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.2M
731.9M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
NXP
ESPR
Price
$14.06
$3.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.75
AVG Volume (30 Days)
155.5K
17.3M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$13.73
$0.76
52 Week High
$14.65
$4.18

Technical Indicators

Market Signals
Indicator
NXP
ESPR
Relative Strength Index (RSI) 43.34 70.72
Support Level $13.91 $2.37
Resistance Level $14.55 $3.15
Average True Range (ATR) 0.13 0.02
MACD -0.02 0.03
Stochastic Oscillator 22.94 37.63

Price Performance

Historical Comparison
NXP
ESPR

About NXP Nuveen Select Tax Free Income Portfolio

Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: